Committee requests more information on gefitinib PAS

The Pharmaceutical Journal Group

首页> 外文期刊>The pharmaceutical journal >Committee requests more information on gefitinib PAS

【24h】

Committee requests more information on gefitinib PAS

机译：委员会要求获得有关吉非替尼PAS的更多信息

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AstraZeneca's patient access scheme for anticancer drug gefitinib (Iressa) has come under fire in National Institute for Health and Clinical Excellence draft guidance issued last week.

机译：阿斯利康抗癌药物吉非替尼（Iressa）的患者进入方案在上周发布的美国国家卫生与临床卓越研究所的指导草案中遭到抨击。

著录项

来源
《The pharmaceutical journal》 |2010年第7588期|共1页
作者
The Pharmaceutical Journal Group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Committee requests more information on gefitinib PAS [J] . The Pharmaceutical Journal Group The pharmaceutical journal . 2010,第7588期

机译：委员会要求获得有关吉非替尼PAS的更多信息
2. Eastern Energy Expo Coming to Hershey, PA Requesting Presentation Applications [J] . Indoor comfort marketing group Indoor comfort marketing . 2016,第6期

机译：东部能源博览会来到宾夕法尼亚州好时市，要求演示应用
3. Pa. driller drops forced pooling request [J] . Mike Lee Greenwire . 2014,第SEPa2期

机译：Pa。司钻放弃强制合并请求
4. AISC CODE OF STANDARD PRACTICE COMMITTEE'S RECOMMENDED STANDARD OF PRACTICE FOR "REQUESTS FOR INFORMATION" (RFIs) [C] . William Andrews North American Steel Construction Conference . 2005

机译：AISC标准练习委员会建议的“信息请求”（RFI）的建议惯例标准
5. Congressional committee requests revisited: Professional expertise, multiple goals and representation. [D] . Faricy, Christopher George. 2006

机译：国会委员会再次提出要求：专业知识，多重目标和代表性。
6. Evaluation of clinical trials by Ethics Committees in Germany - Experience of applicants with the review of requests for opinion of the Ethics Committees - results of a survey among members of the German Association of Research-Based Pharmaceutical Companies (VFA) [O] . Hagen Russ, Susanne Busta, Axel Riedel, 2009

机译：德国伦理委员会对临床试验的评估-审查伦理委员会意见的申请人的经验-德国研究型制药公司协会（VFA）成员的调查结果
7. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)44The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur.55This document was approved by the American College of Cardiology Foundation Board of Trustees in July, 2003, the American Heart Association Science Advisory and Coordinating Committee in July, 2003, and the American Society of Nuclear Cardiology Board of Directors in July, 2003.66When citing this document, the American College of Cardiology Foundation, the American Heart Association, and the American Society of Nuclear Cardiology request that the following citation format be used: Klocke FJ, Baird MG, Bateman TM, Berman DS, Carabello BA, Cerqueira MD, DeMaria AN, Kennedy JW, Lorell BH, Messer JV, O’Gara PT, Russell RO Jr, St. John Sutton MG, Udelson JE, Verani MS, Williams KA. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). J Am Coll Cardiol 2003;42:1318–33.77(J Am Coll Cardiol 2003;42:1318–33)88©2003 by the American College of Cardiology Foundation and the American Heart Association, Inc. [O] . Klocke Francis J, Baird Michael G, Lorell Beverly H, 2003

机译：ACC / AHA / ASNC心脏放射性核素成像临床使用指南-执行摘要美国心脏病学会/美国心脏协会实践指南工作组的报告（ACC / AHA / ASNC委员会，对1995年临床使用指南进行修订ACC / AHA实践指导小组）竭尽全力避免由于写作小组成员的外部关系或个人利益而引起的任何实际或潜在的利益冲突。具体来说，要求写作小组的所有成员提供所有可能被视为实际或潜在利益冲突的关系的披露声明。这些声明由上级工作组审查，在第一次会议上向书面小组的所有成员口头报告，并在发生变化时进行更新。55本文件于2003年7月获得美国心脏病学会基金会董事会的批准。 2003年7月，美国心脏协会科学咨询与协调委员会，2003年7月，美国核心脏病学会理事会。66引用该文件时，美国心脏病学会基金会，美国心脏协会和美国核学会心脏病学要求使用以下引用格式：Klocke FJ，Baird MG，Bateman TM，Berman DS，Carabello BA，Cerqueira MD，DeMaria AN，Kennedy JW，Lorell BH，Messer JV，O'Gara PT，Russell RO Jr，St John Sutton MG，Udelson JE，Verani MS，Williams KA。 ACC / AHA / ASNC心脏放射性核素成像临床使用指南-执行摘要：美国心脏病学会/美国心脏协会实践小组工作指南（ACC / AHA / ASNC委员会，修订1995年临床指南）的报告使用放射性核素成像）。 J Am Coll Cardiol 2003; 42：1318–33.77（J Am Coll Cardiol 2003; 42：1318–33）88©2003美国心脏病学会基金会和美国心脏协会版权所有。

Committee requests more information on gefitinib PAS

摘要

著录项

相似文献

相关主题

期刊订阅